Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment

被引：1
作者：
Wang, Kai-Hung [1 ]
Ding, Dah-Ching [2 ]
机构：
[1] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med Res, Hualien, Taiwan
[2] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Obstet & Gynecol, 707,Sect 3,Chung Yang Rd, Hualien, Taiwan
来源：
TZU CHI MEDICAL JOURNAL | 2021年 / 33卷 / 03期
关键词：
Axl; MerTK; Tyro3; and MerTK receptors; Tumor immune microenvironment; TYROSINE KINASE AXL; SMALL-MOLECULE INHIBITOR; THERAPEUTIC TARGET; GROWTH ARREST; EXPRESSION ANALYSIS; CANCER METASTASIS; BREAST-CANCER; LUNG-CANCER; CELL-GROWTH; C-MER;
D O I：
10.4103/tcmj.tcmj_129_20
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In both normal and tumor tissues, receptor tyrosine kinases (RTKs) may be pleiotropically expressed. The RTKs not only regulate ordinary cellular processes, including proliferation, survival, adhesion, and migration, but also have a critical role in the development of many types of cancer. The Tyro3, Axl, and MerTK (TAM) family of RTKs (Tyro3, Axl, and MerTK) plays a pleiotropic role in phagocytosis, inflammation, and normal cellular processes. In this article, we highlight the cellular activities of TAM receptors and discuss their roles in cancer and immune cells. We also discuss cancer therapies that target TAM receptors. Further research is needed to elucidate the function of TAM receptors in immune cells toward the development of new targeted immunotherapies for cancer.
引用
收藏
页码：250 / 256
页数：7
相关论文
共 114 条
  • [1] The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
    Alvarez, Hector
    Montgomery, Elizabeth A.
    Karikari, Collins
    Canto, Marcia
    Dunbar, Kerry B.
    Wang, Jean S.
    Feldmann, Georg
    Hong, Seung-Mo
    Haffner, Michael C.
    Meeker, Alan K.
    Holland, Sacha J.
    Yu, Jiaxin
    Heckrodt, Thilo J.
    Zhang, Jing
    Ding, Pingyu
    Goff, Dane
    Singh, Rajinder
    Carlos Roa, Juan
    Marimuthu, Arivusudar
    Riggins, Gregory J.
    Eshleman, James R.
    Nelkin, Barry D.
    Pandey, Akhilesh
    Maitra, Anirban
    [J]. CANCER BIOLOGY & THERAPY, 2010, 10 (10) : 1009 - 1018
  • [2] The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
    Antony, Jane
    Tan, Tuan Zea
    Kelly, Zoe
    Low, Jeffrey
    Choolani, Mahesh
    Recchi, Chiara
    Gabra, Hani
    Thiery, Jean Paul
    Huang, Ruby Yun-Ju
    [J]. SCIENCE SIGNALING, 2016, 9 (448)
  • [3] TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy
    Aveic, Sanja
    Corallo, Diana
    Porcu, Elena
    Pantile, Marcella
    Boso, Daniele
    Zanon, Carlo
    Viola, Giampietro
    Sidarovich, Viktoryia
    Mariotto, Elena
    Quattrone, Alessandro
    Basso, Giuseppe
    Tonini, Gian Paolo
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 818 : 435 - 448
  • [4] Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast
    Berclaz, G
    Altermatt, HJ
    Rohrbach, V
    Kieffer, I
    Dreher, E
    Andres, AC
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (06) : 819 - 824
  • [5] Besterman JM, 2010, J CLIN ONCOL, V28
  • [6] Enveloped Viruses Disable Innate Immune Responses in Dendritic Cells by Direct Activation of TAM Receptors
    Bhattacharyya, Suchita
    Zagorska, Anna
    Lew, Erin D.
    Shrestha, Bimmi
    Rothlin, Carla V.
    Naughton, John
    Diamond, Michael S.
    Lemke, Greg
    Young, John A. T.
    [J]. CELL HOST & MICROBE, 2013, 14 (02) : 136 - 147
  • [7] IDENTIFICATION OF 4 MURINE CDNAS ENCODING PUTATIVE PROTEIN-KINASES FROM PRIMITIVE EMBRYONIC STEM-CELLS DIFFERENTIATED IN-VITRO
    BIESECKER, LG
    GOTTSCHALK, LR
    EMERSON, SG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (15) : 7044 - 7048
  • [8] Met, metastasis, motility and more
    Birchmeier, C
    Birchmeier, W
    Gherardi, E
    Vande Woude, GF
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) : 915 - 925
  • [9] AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
    Brand, Toni M.
    Iida, Mari
    Stein, Andrew P.
    Corrigan, Kelsey L.
    Braverman, Cara M.
    Coan, John P.
    Pearson, Hannah E.
    Bahrar, Harsh
    Fowler, Tyler L.
    Bednarz, Bryan P.
    Saha, Sandeep
    Yang, David
    Gill, Parkash S.
    Lingen, Mark W.
    Saloura, Vassiliki
    Villaflor, Victoria M.
    Salgia, Ravi
    Kimple, Randall J.
    Wheeler, Deric L.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2601 - 2612
  • [10] S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
    Burbridge, Mike F.
    Bossard, Celine J.
    Saunier, Carine
    Fejes, Imre
    Bruno, Alain
    Leonce, Stephane
    Ferry, Gilles
    Da Violante, Georges
    Bouzom, Francois
    Cattan, Valerie
    Jacquet-Bescond, Anne
    Comoglio, Paolo M.
    Lockhart, Brian P.
    Boutin, Jean A.
    Cordi, Alex
    Ortuno, Jean-Claude
    Pierre, Alain
    Hickman, John A.
    Cruzalegui, Francisco H.
    Depil, Stephane
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) : 1749 - 1762
12345678910